Histopathology of Vascular Injury in Sprague-Dawley Rats Treated with Phosphodiesterase IV Inhibitor SCH 351591 or SCH 534385
暂无分享,去创建一个
R. Snyder | F. Goodsaid | I. Rosenblum | F. Sistare | E. Herman | A. Knapton | Jun Zhang | R. Honchel | P. Espandiari | J. Hanig | J. Weaver | T. Miller
[1] R. Snyder,et al. Biomarkers in Peripheral Blood Associated with Vascular Injury in Sprague-Dawley Rats Treated with the Phosphodiesterase IV Inhibitors SCH 351591 or SCH 534385 , 2008, Toxicologic pathology.
[2] G. Hanton,et al. Investigation of the molecular mechanisms preceding PDE4 inhibitor-induced vasculopathy in rats: tissue inhibitor of metalloproteinase 1, a potential predictive biomarker. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.
[3] A. Nakamura,et al. Molecular Pathological Evaluation of Clusterin in a Rat Model of Unilateral Ureteral Obstruction as a Possible Biomarker of Nephrotoxicity , 2007, Toxicologic pathology.
[4] Xu-wen Liu,et al. Identification of CD63 as a tissue inhibitor of metalloproteinase‐1 interacting cell surface protein , 2006, The EMBO journal.
[5] L. Mecklenburg,et al. Mesenteritis precedes vasculitis in the rat mesentery after subacute administration of a phosphodiesterase type 4 inhibitor. , 2006, Toxicology letters.
[6] N. Rifai,et al. Mechanisms and Biomarkers of Cardiovascular Injury Induced by Phosphodiesterase Inhibitor III SK&F 95654 in the Spontaneously Hypertensive Rat , 2006, Toxicologic pathology.
[7] S. Kanaly,et al. Characterization of the Inflammatory Response to a Highly Selective PDE4 Inhibitor in the Rat and the Identification of Biomarkers that Correlate with Toxicity , 2006, Toxicologic pathology.
[8] R. Austin,et al. Peroxynitrite Causes Endoplasmic Reticulum Stress and Apoptosis in Human Vascular Endothelium: Implications in Atherogenesis , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[9] R. Radi,et al. Peroxynitrite and drug-dependent toxicity. , 2005, Toxicology.
[10] S. Burchiel,et al. Drug-induced vascular injury--a quest for biomarkers. , 2005, Toxicology and applied pharmacology.
[11] D. Lewis,et al. Heme Oxygenase-1 Mediates Up-Regulation of Adhesion Molecule Expression Induced by Peroxynitrite in Endothelial Cells , 2004, The Journal of the Society for Gynecologic Investigation: JSGI.
[12] P. Blackshear,et al. The Toxicity of SCH 351591, a Novel Phosphodiesterase-4 Inhibitor, in Cynomolgus Monkeys , 2004, Toxicologic pathology.
[13] B. Altura,et al. Peroxynitrite Induces Apoptosis in Rat Aortic Smooth Muscle Cells: Possible Relation to Vascular Diseases , 2004, Experimental biology and medicine.
[14] M. Albassam,et al. Apoptosis and Nitrative Stress Associated with Phosphodiesterase Inhibitor-Induced Mesenteric Vasculitis in Rats , 2003, Toxicologic pathology.
[15] S. Zahler,et al. Crucial role of local peroxynitrite formation in neutrophil-induced endothelial cell activation. , 2003, Cardiovascular research.
[16] M. Reily,et al. Effect of dexamethasone on the metabonomics profile associated with phosphodiesterase inhibitor-induced vascular lesions in rats. , 2002, Toxicology and applied pharmacology.
[17] T. Ashikaga,et al. Regulation of cyclic AMP in rat pulmonary microvascular endothelial cells by rolipram-sensitive cyclic AMP phosphodiesterase (PDE4). , 2002, Biochemical pharmacology.
[18] V. Ferrans,et al. SK&F 95654-Induced Acute Cardiovascular Toxicity in Sprague-Dawley Rats—Histopathologic, Electron Microscopic, and Immunohistochemical Studies , 2002, Toxicologic pathology.
[19] Shao-Ling Zhang,et al. Peroxynitrite induces integrin‐dependent adhesion of human neutrophils to endothelial cells via activation of the Raf‐1/MEK/Erk pathway , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[20] S. Pruett,et al. Quantitative Analysis of the Neuroendocrine–Immune Axis: Linear Modeling of the Effects of Exogenous Corticosterone and Restraint Stress on Lymphocyte Subpopulations in the Spleen and Thymus in Female B6C3F1 Mice , 2000, Brain, Behavior, and Immunity.
[21] J. Bauer,et al. Nitrotyrosine causes selective vascular endothelial dysfunction and DNA damage. , 2000, Journal of cardiovascular pharmacology.
[22] C. Sargent,et al. Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. , 2000, Immunopharmacology.
[23] Nakahata,et al. The effects of anti‐asthma drugs on mediator release from cultured human mast cells , 1998, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[24] J. Rosenbaum,et al. Ultrastructural Immunolocalization of Basic Fibroblast Growth Factor in Mast Cell Secretory Granules: Morphological Evidence for bFGF Release Through Degranulation , 1998, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[25] H. Dvorak,et al. Mast Cells Can Secrete Vascular Permeability Factor/ Vascular Endothelial Cell Growth Factor and Exhibit Enhanced Release after Immunoglobulin E–dependent Upregulation of Fcε Receptor I Expression , 1998, The Journal of experimental medicine.
[26] B. Ballermann,et al. Endothelial cell activation. , 1998, Kidney international.
[27] C. Ferran,et al. Protective genes expressed in endothelial cells: a regulatory response to injury. , 1997, Immunology today.
[28] P. Peachell,et al. Effects of phosphodiesterase inhibitors on human lung mast cell and basophil function , 1997, British journal of pharmacology.
[29] Andrew N. Rowan. Guide for the Care and Use of Laboratory Animals , 1996 .
[30] H. Dvorak,et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. , 1995, The American journal of pathology.
[31] M. Boros,et al. RESPONSE OF MUCOSAL MAST CELLS TO INTESTINAL ISCHEMIA-REPERFUSION INJURY IN THE RAT , 1995, Shock.
[32] C. Oliver,et al. The rat mast cell antigen AD1 (homologue to human CD63 or melanoma antigen ME491) is expressed in other cells in culture. , 1992, Journal of immunology.
[33] A. Tonnel,et al. Endothelial cells , 1991 .
[34] B. Undem,et al. Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. , 1991, Thorax.
[35] G. Pauli,et al. EFFECTS OF CYCLIC AMP‐ AND CYCLIC GMP‐PHOSPHODIESTERASE INHIBITORS ON IMMUNOLOGICAL RELEASE OF HISTAMINE AND ON LUNG CONTRACTION , 1981, British journal of pharmacology.
[36] B. Leblanc,et al. Characterization of the arteritis induced by infusion of rats with UK-61,260, an inodilator, for 24 h , 2009, Archives of Toxicology.
[37] L. Liaudet,et al. Nitric oxide and peroxynitrite in health and disease. , 2007, Physiological reviews.
[38] M. Reily,et al. Metabonomic assessment of vasculitis in rats , 2007, Cardiovascular Toxicology.
[39] G. Guigon,et al. Altered gene expression in rat mesenteric tissue following in vivo exposure to a phosphodiesterase 4 inhibitor. , 2007, Toxicology and applied pharmacology.
[40] K. Doi,et al. Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators. , 2002, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.
[41] L. Viera,et al. Immunohistochemical methods to detect nitrotyrosine. , 1999, Methods in enzymology.
[42] J. Lebreton,et al. Biochemical and Molecular Roles of Nutrients Induction and Modulation of Acute-Phase Response by Protein Malnutrition in Rats : Comparative Effect of Systemic and Localized Inflammation on Interleukin-6 and Acute-Phase Protein Synthesis 1 , 2 , 1998 .
[43] D. Underwood,et al. The influence of endogenous catecholamines on the inhibitory effects of rolipram against early- and late-phase response to antigen in the guinea pig. , 1997, The Journal of pharmacology and experimental therapeutics.
[44] J. Larson,et al. The toxicity of repeated exposures to rolipram, a type IV phosphodiesterase inhibitor, in rats. , 1996, Pharmacology & toxicology.
[45] M. Giembycz,et al. 7 – Interaction of PDE4 Inhibitors with Enzymes and Cell Functions , 1996 .
[46] J. Rosenbaum,et al. Mast cells are a major source of basic fibroblast growth factor in chronic inflammation and cutaneous hemangioma. , 1995, The American journal of pathology.